Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
These trials test retatrutide for obesity, type 2 diabetes, cardiovascular disease, knee osteoarthritis, and liver disease (Giblin et al., Diabetes, Obesity and Metabolism 2026)
Human evidence - Phase 3 TRIUMPH-1 (Eli Lilly, May 21, 2026) 2,339 adults with obesity or overweight without diabetes
The active ingredient in semaglutide GLP-1 injections is a type of GLP-1 receptor agonist
This emerging option has shown potential benefits not only for weight management but also for areas such as metabolic health, insulin regulation, and long-term wellness
Table 3 Other related KEGG pathways are listed below
US$ 26.04
US$ 23.99
US$ 26.89
US$ 29.57
US$ 29.88
US$ 23.61
